Meeting
2012 ASCO Annual Meeting
Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC).
Authors
Giuseppe Gullo
St Vincent's University Hospital, Dublin, Ireland
Giuseppe Gullo , Monica Zuradelli , Francesco Sclafani , Josephine Ballot , Anne Marie Defrein , Armando Santoro , John Crown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 615)
DOI
10.1200/jco.2012.30.15_suppl.615
Abstract #
615
Poster Bd #
11B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Long-term follow up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic breast cancer (MBC).
First Author: Giuseppe Gullo
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop
Poster
2022 ASCO Annual Meeting
Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
First Author: Zhonghui Ou